NASDAQ: BOLDBoundless Bio Inc Stock
$1.42+0.11 (+8.4%)
Updated Apr 17, 2025
BOLD Price
$1.42
Fair Value Price
-$1.24
Market Cap
$31.67M
52 Week Low
$1.06
52 Week High
$12.65
P/E
-0.37x
P/B
0.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$65.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$61M
Beta
1.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BOLD Overview
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BOLD's potential to beat the market
- BOLD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BOLD
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important BOLD news, forecast changes, insider trades & much more!
BOLD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BOLD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BOLD ($1.42) is overvalued by 214.6% relative to our estimate of its Fair Value price of -$1.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BOLD ($1.42) is not significantly undervalued (214.6%) relative to our estimate of its Fair Value price of -$1.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BOLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BOLD due diligence checks available for Premium users.
Valuation
BOLD fair value
Fair Value of BOLD stock based on Discounted Cash Flow (DCF)
Price
$1.42
Fair Value
-$1.24
Undervalued by
214.60%
BOLD ($1.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BOLD ($1.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BOLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BOLD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.37x
Industry
-177.72x
Market
27.98x
BOLD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.21x
Industry
4.05x
BOLD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BOLD's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.4M
Profit Margin
0%
BOLD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$206.4M
Liabilities
$55.8M
Debt to equity
0.37
BOLD's short-term assets ($154.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BOLD's short-term assets ($154.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BOLD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.6M
Investing
$1.8M
Financing
$113.0k
BOLD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BOLD vs Biotech Stocks
Boundless Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.